More Cases of Drug-Resistant Tuberculosis Complicate Care but Spur Global Research and Innovation
Authors: Jennifer Fisher Wilson
Journal: Annals of Internal Medicine (2009)

Current Clinical Issues17 March 2009More Cases of Drug-Resistant Tuberculosis Complicate Care but Spur Global Research and InnovationJennifer Fisher WilsonJennifer Fisher WilsonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-6-200903170-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail For most Americans, neither tuberculosis treatment nor prevention is a concern or a priority. Effective tuberculosis care has made this dangerous disease quite rare in the United States. In 2006, just 13 767 cases were reported (4.6 cases per 100 000 population), 56.7% of which were among foreign-born persons (1).But for many people elsewhere in the world, tuberculosis is a constant threat. The disease, with its symptomatic coughing, weight loss, fatigue, fever, and pleurisy, is a leading cause of mortality. It results in approximately 1.7 million deaths annually, according to the World Health Organization (WHO). Most of these deaths occur in ...References1. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis incidence—United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56:245-50. MedlineGoogle Scholar2. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. N Engl J Med. 1995;333:229-33. CrossrefMedlineGoogle Scholar3. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119-28. CrossrefMedlineGoogle Scholar4. Shin SS, Yagui M, Ascencios L, Yale G, Suarez C, Quispe N, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis. 2008;14:701-8. CrossrefMedlineGoogle Scholar5. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:241. [PMID: 16796403] CrossrefMedlineGoogle Scholar6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. CrossrefMedlineGoogle Scholar7. Loveday M, Thomson L, Chopra M, Ndlela Z. A health systems assessment of the KwaZulu-Natal tuberculosis programme in the context of increasing drug resistance. Int J Tuberc Lung Dis. 2008;12:1042-7. [PMID: 18713502] MedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Jennifer Fisher WilsonDisclosures: None disclosed.E-mail:jenwilson@acponline.org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPotential Selective Inhibitors against Rv0183 of Mycobacterium tuberculosis Targeting Host Lipid Metabolism 17 March 2009Volume 150, Issue 6Page: 433-436KeywordsBacteriaDirectly observed therapy short courseDrugsHIVIsoniazidMultidrug resistant tuberculosisPatientsScientistsTuberculosisTuberculosis drug discovery ePublished: 17 March 2009 Issue Published: 17 March 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...